Compare · BNTX vs GMDA
BNTX vs GMDA
Side-by-side comparison of BioNTech SE (BNTX) and Gamida Cell Ltd. (GMDA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and GMDA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $24.78B, about 142.6x GMDA ($173.7M).
- BNTX has hit the wire 13 times in the past 4 weeks while GMDA has been quiet.
- BNTX has more recent analyst coverage (25 ratings vs 3 for GMDA).
- Company
- BioNTech SE
- Gamida Cell Ltd.
- Price
- $98.72+3.03%
- $0.03-11.65%
- Market cap
- $24.78B
- $173.7M
- 1M return
- +6.42%
- -
- 1Y return
- +2.50%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2018
- News (4w)
- 13
- 0
- Recent ratings
- 25
- 3
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Gamida Cell Ltd.
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Latest BNTX
- Chief Executive Officer Sahin Ugur sold $4,721,976 worth of Ordinary Shares (49,000 units at $96.37) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 553,209 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Executive Officer Sahin Ugur sold $8,439,336 worth of Ordinary Shares (86,000 units at $98.13) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 602,209 units (SEC Form 4)
- SEC Form 6-K filed by BioNTech SE
- BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
- Chief Executive Officer Sahin Ugur sold $1,974,287 worth of Ordinary Shares (20,500 units at $96.31) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 688,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $7,190,663 worth of Ordinary Shares (73,000 units at $98.50) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 708,709 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $7,889,055 worth of Ordinary Shares (76,500 units at $103.12) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 781,709 units (SEC Form 4)
- BioNTech downgraded by BMO Capital Markets with a new price target
- SEC Form 6-K filed by BioNTech SE
Latest GMDA
- Purple Biotech Appoints Shai Lankry as Chief Financial Officer
- HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
- SEC Form EFFECT filed by Gamida Cell Ltd.
- SEC Form EFFECT filed by Gamida Cell Ltd.
- SEC Form EFFECT filed by Gamida Cell Ltd.
- Gamida Cell Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits (Amendment)
- SEC Form S-8 POS filed by Gamida Cell Ltd.
- SEC Form S-8 POS filed by Gamida Cell Ltd.
- SEC Form S-8 POS filed by Gamida Cell Ltd.
- SEC Form POS AM filed by Gamida Cell Ltd.